ABSTRACT
Objective: To explicitly apply Failure Model and Effects Analysis (FMEA) to enhance the effectiveness of hospital infection prevention and control in the Lhasa region, with a focus on reducing infection rates and improving emergency response strategies. Methods: This study utilized a hybrid FMEA approach, combining qualitative expert insights with quantitative data analysis, to assess hospital infection risks from January 2019 to June 2023 in Lhasa hospitals. Results: The FMEA analysis led to the development of targeted strategies for key prevention and control links. For instance, implementing a real-time monitoring system for early detection of infections and enhancing staff training on infection control protocols. Conclusion: The FMEA-based system, adaptable to various healthcare settings, demonstrated potential scalability beyond the Lhasa region, offering a promising framework for improved hospital infection control globally.
ABSTRACT
PURPOSE: To comprehensively investigate the optimal multimodal treatment of resectable esophagogastric junction (EGJ) cancer. METHODS: PubMed, Embase, Cochrane Library and Web of Science were searched until March 11, 2022. The outcomes were overall survival (OS), locoregional and distant recurrence, and R0 resection. Network plots, forest plots and league tables were drawn for each outcome. Rank probabilities for different treatments in each outcome were also depicted. RESULTS: A total of 23 studies with 18,319 EGJ participants were included. No significant differences in OS between any two of the 6 treatments. Perioperative chemoradiotherapy (pCRT) had the highest probability (36.03%) to be the optimal treatment as regards OS. Patients undergoing pCRT had a significantly lower incidence of locoregional recurrence than those undergoing adjuvant chemotherapy (aCT), neoadjuvant chemotherapy (nCT), perioperative chemotherapy (pCT), or surgery alone (S). Patients with pCRT had the greatest likelihood (68.86%) to have the lowest incidence of locoregional recurrence. Comparable impacts of the 6 treatments on the incidence of distant recurrence, and pCRT was most likely (46.65%) to be the optimal treatment with respect to distant recurrence. Neoadjuvant CRT (nCRT) was associated with a significantly increased incidence of R0 resection compared with nCT or S, and nCRT had the highest probability (97.68%) to be the best therapy regarding R0 resection. CONCLUSION: For patients with resectable EGJ cancer, pCRT may be the optimal multimodal treatment regarding survival and recurrence.
